Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Shares Outstanding (2023 - 2025)

Beta Bionics (BBNX) has disclosed Shares Outstanding for 3 consecutive years, with $44.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 565.3% to $44.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.4 million through Dec 2025, up 565.3% year-over-year, with the annual reading at $44.4 million for FY2025, 565.3% up from the prior year.
  • Shares Outstanding hit $44.4 million in Q4 2025 for Beta Bionics, up from $44.0 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $44.4 million in Q4 2025 to a low of $6.0 million in Q4 2023.
  • Historically, Shares Outstanding has averaged $23.0 million across 3 years, with a median of $6.7 million in 2024.
  • Biggest five-year swings in Shares Outstanding: grew 10.74% in 2024 and later skyrocketed 619.91% in 2025.
  • Year by year, Shares Outstanding stood at $6.0 million in 2023, then increased by 10.74% to $6.7 million in 2024, then skyrocketed by 565.3% to $44.4 million in 2025.
  • Business Quant data shows Shares Outstanding for BBNX at $44.4 million in Q4 2025, $44.0 million in Q3 2025, and $43.5 million in Q2 2025.